Identifying and Solving Top Challenges to Oncology Biomarker Testing

David L. Rimm, MD, PhD; Roy S. Herbst, MD, PhD

Drs. David Rimm and Roy Herbst identify the top challenges in the area of biomarker testing as well as solutions to these challenges, including availability of sufficient tissue for a large number of biomarker assays, the time some biomarker tests require for completion, the need for a tight association of test results with clinical outcomes, and the development of companion diagnostics for certain immunotherapies.

Related Videos

October 16, 2015

Pembrolizumab vs. Ipilimumab

Dr. Sanjiv Agarwala discusses the pros and cons of using Pembrolizumab over anti-CTLA4 antibody therapy.

November 26, 2013

PMO Interview with the Innovator Series: Volume 7

Listen as some of the top academic and community thought leaders in multiple myeloma define what precision medicine means to them.